ArticleGastro hep advances2026
Unrecognized Fibrosis Risk in MASLD: A Real-World Analysis and the Case for AI-Augmented Stratification.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Current fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) relies on provider-initiated noninvasive testing and referral, making it vulnerable to variability in awareness, documentation, and follow-through. We aimed to quantify care gaps associated with this provider-dependent approach and explore opportunities for artificial intelligence to improve MASLD detection and management. Methods: We performed a retrospective analysis of all adults undergoing abdominal ultrasound in 2024 at Ochsner Health's South Shore campuses. Natural language processing identified reports with hepatic steatosis, and patients with at least 1 cardiometabolic risk factor were included. Fibrosis-4 index (FIB-4) scores were calculated from recent laboratory data (within 6 months of ultrasound) using age-adjusted thresholds to classify patients as low, indeterminate, or high fibrosis risk. Management was defined as hepatology referral for high- or indeterminate-risk patients and documentation of a primary care provider for low-risk patients requiring reassessment. Results: Among 14,814 adults with ultrasound in 2024, 3052 (20.6%) met the MASLD criteria. Based on age-adjusted FIB-4, 15.2% were high risk, 18.0% indeterminate, and 66.0% low risk for advanced fibrosis. Of 465 high-risk patients, only 33.5% had hepatology referrals, leaving 309 (10.1% of the MASLD cohort) without appropriate specialty evaluation. Among 549 indeterminate-risk patients, 58.7% lacked referral for secondary assessment. In the low-risk group, 224 (7.3%) had no documented primary care provider for follow-up, and 24 (0.8%) lacked sufficient laboratory data for FIB-4 calculation. Overall, 28.0% of the MASLD cohort had a critical, moderate, or monitoring care gap. Conclusion: Significant gaps persist in MASLD fibrosis risk stratification and management, largely reflecting system-level coordination failures rather than access barriers. Artificial intelligence-driven workflows integrated into the electronic health record could automate steatosis detection, calculate FIB-4 scores, flag care gaps, and prompt risk-stratified referrals or reassessments, offering a scalable solution to standardize MASLD management and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.